Search results for Junshi Xie, Instruments, News and Company Profiles

Name		Stock exchange	Average volume	Price	Type
SHANGHAI JUNSHI BIOSCIENCES CO., LTD.	688180	Shanghai S.E.	6,293,393	30.14 CNY	Stock
SHANGHAI JUNSHI BIOSCIENCES CO., LTD.	1877	Hong Kong S.E. +2 Other	1,188,739	11.76 HKD	Stock
SHANGHAI JUNSHI BIOSCIENCES CO., LTD.	SHJBF	OTC Markets	0	1.86 USD
SHANGHAI JUNSHI BIOSCIENCES CO., LTD.	8SJ	Deutsche Boerse AG	-	1.4 EUR

News (26)

ZTE releases 2022 Sustainability Report	23-05-25	AQ
ZTE, Ooredoo Group extend partnership agreement for further five years	23-03-08	AQ
Junshi Biosciences Announces NEJM Publication of Results of Phase 3 Study of VV116 Versus PAXLOVID for Adults at High Risk for Progression to Severe COVID-19	22-12-29	GL
Shanghai Junshi Biosciences Co., Ltd Announces Nejm Publication of Results of Phase 3 Study of Vv116 Versus Paxlovid for Adults At High Risk for Progression to Severe Covid-19	22-12-29	CI
ZTE : Releases 2021 Sustainability Report	22-06-16	PU
Shanghai Junshi Biosciences Co., Ltd. Announces Results of the Preclinical in Vivo Efficacy Study of VV116 as a Potent Inhibitor of RSV	22-04-18	CI
ZTE hosts Global Analyst Conference 2021 online	21-10-26	PU
ZTE Chief Operating Officer Xie Junshi: Strengthening ZTE's resilience to achieve rapid growth	21-10-25	PU
ZTE : Releases 2020 Sustainability Report	21-05-20	AQ
Arctic Vision : Announces Completion of Over US$100 Million Series B Financing to Accelerate Portfolio Expansion, Clinical Development and Commercialization	21-03-09	PR
Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development	21-03-01	PR
ZTE Corporation : - Announcement Completion of Registration of the First Grant of Share Options under the 2020 Share Option Incentive Scheme	20-12-02	AQ
Junshi Biosciences and Wigen Biomedicine Enter Global Development and Commercialization Collaboration for Four Small Molecule Cancer Drug Candidates	20-09-16	AQ
Junshi Biosciences and Wigen Biomedicine Enter Global Development and Commercialization Collaboration for Four Small Molecule Cancer Drug Candidates	20-09-16	GL
Junshi Biosciences and Wigen Biomedicine Enter Global Development and Commercialization Collaboration for Four Small Molecule Cancer Drug Candidates	20-09-16	AQ
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - ENTERING INTO THE TECHNOLOGY TRANSFER AND COOPERATION AGREEMENT WITH WIGEN BIOMEDICINE	20-09-16	PU
ZTE : INTERIM REPORT 2020	20-09-10	PU
Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON APPOINTMENT OF SENIOR MANAGEMENT	20-08-28	PU
ZTE : 2020 INTERIM REPORT SUMMARY AND RESULTS ANNOUNCEMENT	20-08-28	PU
China Education : ANNUAL REPORT 2018/2019	19-12-19	PU
China Education : ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 AUGUST 2019	19-11-26	PU
ZTE : 2019 THIRD QUARTERLY REPORT	19-10-28	PU
Zte Corporation Announces Appointment of Xie Junshi as Executive Vice President	19-09-19	CI
ZTE : Announcement Resolutions of the Ninth Meeting of the Eighth Session of the Board of Directors	19-09-19	PU
European Commission : CALENDRIER du 05 novembre au 11 novembre 2018	18-10-31	PU
ZTE : Exclusively Wins SWAN Slovakia Contract for Nationwide LTE Networks	14-08-27	BU

Companies (3)

COHERUS BIOSCIENCES, INC. 222 M $

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its immuno-oncology pipeline includes multiple antibody immunotherapy ...

SHANGHAI JUNSHI BIOSCIENCES CO., LTD. 3 518 M $

Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products ...

SHANGHAI JUNSHI BIOSCIENCES CO., LTD. 3 518 M $

Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products ...

Insiders

Junshi Saito

Junshi Wang

Junshi Yamaguchi

Junshi Yamaguchi served as the Chairman, President & Chief Executive Officer of NEC Electronics Corp.
from 2009 to 2010.
Prior to that, he was the Chairman of Renesas Electronics Corp.
He received his undergraduate degree from Keio University.

Junshi Mizuno

Junshi Minagawa

Junshi Wu

Junshi Wu currently works as an Equity Associate at Jefferies LLC.

Junshi Liu

Junshi Liu, Vice President Junshi is a Vice President focused on the Cathay Smart Energy Fund and is based in Beijing.
Before joining Cathay in 2020, Junshi worked as an Investment Associate in Gaorong Capital for 1.5 years, concentrated on technology investments.
Prior to that, He worked as an Analyst with Yunfeng Capital covering investment deals in the technology sector.
In addition, he worked as a Senior Engineer in the 2012 laboratory of Huawei.
Junshi holds a Ph.D.
and B.S.
degree in Electronic Engineering from Zhejiang University and was a visiting scholar at Purdue University.

Junshi Matsuoka

Junshi Iguchi

Junshi Iguchi is currently working as the Director, Head-HR, Legal, Compliance & Audit at Vital KSK Holdings, Inc.

No results for this search

Advanced search

Instruments

News (26)

Companies (3)

Insiders